With over $730 million in 2023 revenue, having provided approximately 800,000 patients with financial assistance, and named the 23rd largest charity in the country on the 2023 Forbes Top 100 List of Largest US Charities, HealthWell Foundation is an independent non-profit that offers co-payment and insurance premium assistance to inadequately insured Americans to allow them to afford their chronic/life-altering medications.As part of senior management, I supervise the influx of revenue/stakeholder outreach/communications and help Board and staff manage the financial viability and strategic planning of the organization. My primary responsibilities are to lead all fundraising efforts for the Foundation's programs by securing donation revenue from and managing relationships with pharmaceutical industry donors and individual/non-profit givers. The foundation averaged approximately $60 million in donations prior to my employ.Significant funding accomplishments include:- FY 2023, $730 million in contributions, resulting in $1 billion in patient programming- FY 2022, $678 million in donation revenue, resulting in 180,000 patient grant awards- FY 2021, raised over $538 million, which enabled us to assist more than 170,000 patients with copays/premiums- In 2020, led efforts to fundraise over $546 million in revenue, awarding grants to over 170,000 patients for medication copay/insurance premium assistance- In 2019, raised over $481 million, which enabled us to award grants to over 160,000 patients- In 2018, total revenue raised was over $427 million, which allowed us to assist more than 117,000 patients- In 2017, total revenue raised was over $350 million and allowed us to provide more than 88,000 patients with copays grantsAdditional responsibilities include assistance with completion of legal and business contracts, regulatory compliance, strategic third party relations, personnel/process management for marketing and outreach activities, and vendor management.

ETX Pharma is a clinical stage pharmaceutical start-up focused on the development of a variety of small molecule drugs in the gastrointestinal (GI) space. As a co-founder, my priority is to increase enterprise value, with specific duties to include:- In-licensing of all corporate assets; ETX-101, ETX-201, ETX-301- all completed and executed- Functioning as corporate Secretary and Treasurer- Assistance with setting up and maintaining corporate financial documents - Assistance with fundraising, both dilutive and non-dilutive - Completion of vendor and partner contracts, including fee-for-service, risk sharing, and other structures- Presentations to current and future stakeholders

Sequella is a clinical stage biotech company focused on the development of infectious disease/ gastrointestinal/oncology therapeutics and diagnostics/devices. The company’s initial concentration was the development of small molecules and diagnostics for tuberculosis, and now also includes research and development efforts in candidiasis, Crohn’s Disease, Helicobacter pylori, gastric cancer, and c. difficile infections. I was an Officer with the company reporting to the CEO and Chair of the Board. Key accomplishments include:• Completed the first industry transaction in the tuberculosis space in the last 40 years to include standard terms for upfront payments to Sequella, near-term milestone payments, and high royalty payments. Deal was valued by BioWorld Today at over $100M.• Creatively in-licensed 2 major corporate assets from big Pharma (Daiichi-Sankyo and Pfizer), resulting in clinical leads for 2 different therapeutic areas, providing a multi-fold corporate valuation increase.• Out-licensed of non-core technology to LabCorp for standard upfront/milestones/royalty • Drafted and negotiated many creative contracts with Sequella vendors, which conserved tens of millions of dollars, incentivized preferred treatment of Sequella, and engendered significant price discounts; thereby helping to manage cash flow and cash reserve.• Functions as in-house Corporate Counsel (and work in tandem with external Counsel when utilized); create, negotiate, review, and execute all corporate/legal Agreements (more than 200 completed during tenure); all of which were reviewed positively by auditors and due diligencers.• As a member of the Senior Management team, planned and executed corporate fundraising strategies with high net worth investors, Investment Banks, Venture Capitalists, philanthropics, and non-dilutive/government sources (company has raised over $70 million during my tenure)

Gene Logic (NASDAQ:GLGC) is a genomics-based drug discovery and development-enabling organization with multi-million dollar research collaborations with the majority of the world’s largest pharmaceutical organizations. I initially joined TherImmune Research Corporation, which was wholly acquired in December, 2002. Led TherImmune’s sales and marketing force while seeking/helping to complete a strategic corporate merger/acquisition. Within two months, we had completed a binding Letter of Agreement to be acquired by Gene Logic, which was consummated on April 1, 2003. I then led Business Development and Marketing for the drug development arm of the merged company.• Key Accomplishment was to assist the rest of the management team in the completion of the M&A transaction. Deal was consummated and resulted in a final negotiated per share price that was a 40% premium to the last private round of stock.

Having raised nearly $1.5 billion during its IPO and leveraging a strong genomics Intellectual Property position, CuraGen (NASDAQ:CRGN) was a leading biotechnology drug discovery and development organization whose efforts have been concentrated in the creation of monoclonal, protein, and small molecule therapeutics for inflammation, oncology, metabolic diseases, and CNS disorders. Duties include:• Overseeing of the prioritization, valuation, and partnering of company’s intellectual property, primarily consisting of development candidates and gene targets• Management of both service-based collaborative research agreements and the negotiation of co-development disease program agreements which have historically been valued between $200 million-$1.4 billion, involving shared risk, royalty distribution, and equity placements• Supervision of division personnel and budget that added $30 million to fee-for-service research collaboration revenues

With 18,000 employees worldwide in 40 different countries and annual revenues of approximately $2 billion, Quintiles Transnational is the world’s largest contract healthcare consulting, product development, marketing, and sales organization. Key Accomplishments during my tenure include:• Achieved over $50 million in sales/contract valuation annually during every year of my tenure, which was recognized as amongst the highest individually in the organization.• Participation in the creation of the very first hybrid equity/risk sharing model within the pharmaceutical industry between sponsors and vendors. Was on the due diligence team analyzing dozens of different opportunities in the fields of Infectious Diseases, Immunology, Allergy/Respiratory, Dermatology, Endocrinology, Gastroenterology, and Medical Devices. 6 of the deals were eventually completed with an approximate valuation of $150-200 million. • Had both P&L and personnel management responsibility for various Strategic Business Units within the company during part of my tenure. Showed both an increase in top line and bottom line efficiency (increasing P&L of the unit 7.5 fold).• Grew and managed a group of 20 in the business development, proposal writing, budgeting, and marketing group and eventually had management responsibility for a group of 50 operational staff• Implemented and led successful business and proposal development system for “targeted”contract clinical research opportunities in assigned therapeutic areas resulting in a 40% increase in strike rate (total short term expected contract revenue = $65 million)• Increased corporate revenues by $300,000 through the providing of product development advice to pharmaceutical and biotechnology manufacturers on a paid consulting basis, which includedworldwide regulatory and clinical strategy development for compounds/biologics

Previous employment was as the business development manager in the strategic development department of a leading public Phase I clinical and bioanalytical contract research organization in the pharmaceutical and biotechnological fields. The position reported directly to the President and included primary contact and business management responsibilities for clients located throughout North America. Company merged with Aster-Cephac. Key accomplishments include:• Corporate top-line revenue increase of 55% during my tenure. I was personally responsible for the signing of the majority of new clients for the firm.• Completely overhauled the marketing materials and scientific publications from the firm, along with modernizing the client database. Led to a 30% increase in new leads for sales staff.